A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation.
The therapeutic potential of cannabinoids has been described previously for several inflammatory diseases, but the molecular mechanisms underlying the anti-inflammatory properties of cannabinoids are not well understood. In this study, we investigated the mechanism of action of a novel synthetic cannabinoid, [(+)(6aS,10aS)-6,6-Dimethyl-3-(1,1-dimethylheptyl)-1-hydroxy-9-(1H-imidazol-2-ylsulfanylmethyl]-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran (PRS-211,092) that has no psychotropic effects but exhibits immunomodulatory properties. Treatment with PRS-211,092 significantly decreased Concanavalin A-induced liver injury in mice that was accompanied by: 1) promotion of early gene expression of interleukin (IL)-6 and IL-10 that play a protective role in this model; 2) induction of early gene expression of the suppressors of cytokine signaling (SOCS-1 and 3), followed by 3) inhibition of several pro-inflammatory mediators, including IL-2, monocyte chemoattractant protein-1 (MCP-1), IL-1beta, interferon-gamma, and tumor necrosis factor alpha. Based on these results, we propose a mechanism by which PRS-211,092 stimulates the expression of IL-6, IL-10 and the SOCS proteins that, in turn, negatively regulates the expression of pro-inflammatory cytokines. Negative regulation by PRS-211,092 was further demonstrated in cultured T cells, where it inhibited IL-2 production and nuclear factor of activated T cells activity. These findings suggest that this cannabinoid derivative is an immunomodulator that could be developed as a potential drug for hepatitis as well as for other short- or long-term inflammatory diseases.
Lavon
Iris
I
Pharmos LTD, Kiryat Weizmann, Bld #13b, Rehovot 76326, Israel. lavoni@netvision.net.il
Sheinin
Tatiana
T
Meilin
Sigal
S
Biton
Efrat
E
Weksler
Ayelet
A
Efroni
Gilat
G
Bar-Joseph
Avi
A
Fink
George
G
Avraham
Ayelet
A
D000276:Adjuvants, Immunologic / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002186:Cannabinoids / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use*; D003208:Concanavalin A / Q000633:toxicity; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D005260:Female; D006520:Hepatitis, Animal / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C
D000276:Adjuvants, Immunologic; D002186:Cannabinoids; D016207:Cytokines; D003208:Concanavalin A